Financials
Financial year 2025
PHARMOVAN from Leuven, company number BE0439974380, closed financial year 2025 with a result of € 127,911 after tax. For that financial year PHARMOVAN recorded a gross margin of € 303,869 and equity of € 249,395. Compared with financial year 2024, the result moved from € 179,564 to € 127,911. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.
€ 249,395
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 127,911
▼ 29% vs 2024
Profit after tax over the fiscal year.
€ 145,937
▼ 24% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 127,500 paid out
100 % of the profit went to the shareholders, mostly to MANAGEMENT CAROLINE VANDECASTEELE (100 % of the shares). That is where the money ends up.
People and assets in 2025
1.5
Average over the fiscal year, from the social balance sheet.
€ 134,425
▲ 6% vs 2024
€ 89,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 7,620
▲ 102% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 79,495
▼ 18% vs 2024
€ 23,041 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 146,039
▲ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 21,475
▲ 33% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 317,871 | € 296,600 | € 350,767 | € 303,869 | ▼ 13% |
| Profit after taxes | € 177,561 | € 147,036 | € 179,564 | € 127,911 | ▼ 29% |
| Equity | € 248,885 | € 248,921 | € 248,985 | € 249,395 | |
| Total debts | € 450,692 | € 382,147 | € 427,696 | € 376,918 | ▼ 12% |
| Cash | € 264,712 | € 185,902 | € 192,693 | € 145,937 | ▼ 24% |
| Land & buildings | € 2,766 | € 2,170 | € 4,013 | € 2,904 | ▼ 28% |
| Retained profit | € 187,385 | € 187,421 | € 187,485 | € 187,895 | |
| Dividend | € 177,500 | € 147,000 | € 179,500 | € 127,500 | ▼ 29% |
| Bank debt | € 113,890 | € 96,327 | € 96,682 | € 79,495 | ▼ 18% |
| Balance sheet total | € 699,577 | € 631,068 | € 676,681 | € 626,313 | ▼ 7% |
| Employees (FTE) | 1.5 | 1.5 | 1.5 | 1.5 |
Key figures of PHARMOVAN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMOVAN?
What happened at PHARMOVAN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Norbert Vandecasteele stepped down as director. NBB
- Management Caroline Vandecasteele BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 127,911 (▼ 29% vs 2024). Source: NBB ↗
- Norbert Vandecasteele became a director. NBB
- Management Caroline Vandecasteele BV became a director. NBB
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 177,561 profit in 2022 to € 127,911 profit in 2025.
Paid € 54,747 in corporate taxes since 2022.
Best year ever: 2024, with € 179,564 profit.
On average € 202,600 of value added per employee in 2025.
A new publication or filing at PHARMOVAN? We notify you, reason included.
Follow PHARMOVANDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of MANAGEMENT CAROLINE VANDECASTEELE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMOVANThe shares are held by MANAGEMENT CAROLINE VANDECASTEELE (100%).
Directors
According to the 2025 annual accounts
Norbert Vandecasteele
Director
since 2021 · until 2027
Management Caroline Vandecasteele BV
Managing director · represented by Vandecasteele Caroline
since 2021 · until 2027
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Aarschotsesteenweg 537
3012 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0439.974.380
- VAT number
- BE 0439.974.380
- Registered office
- Aarschotsesteenweg 537, 3012 Leuven
- Names & denominations
- PHARMOVAN
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 December 1989
- Peppol
- Active · Active since 5 Jul 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers